Adivo GmbH and Bayer Animal Health GmbH have entered into a global collaboration to develop therapeutic antibodies for veterinary medicine. Under this agreement, Bayer Animal Health will receive access to Adivo's antibody technology. Financial details were not disclosed.
Adivo and Bayer have agreed to jointly develop species-specific therapeutic monoclonal antibodies (Editor's note: immunoglobulins, which are produced from a single cell clone and used to diagnose and treat various diseases, to meet the demand for innovative therapies for companion animals.
The aim of the companies is to provide veterinarians with new and innovative treatments in order to offer alternatives to their patients with diseases that are currently inadequately treatable.
Know-how combined with experience
Dr. Douglas Hutchens, Head of Drug Discovery, External Innovation & Chief Veterinary Officer at Bayer Animal Health says:
"The [...] agreement is another example of how we are implementing our innovation strategy: We are combining the expertise of creative startups like Adivo with Bayer's research and development experience to expand our therapeutic options and complement our portfolio. We are constantly looking for innovative technologies that enable us to develop new treatment options for the companion animal sector. We are now focused on advancing the options offered by Adivo from the research and development of therapeutic antibodies to market readiness."
Dr. Kathrin Ladetzki-Baehs, Managing Director of Adivo, explains that the company is convinced that pets have a positive impact on our society. By developing innovative, effective medications, the Munich-based company aims to offer veterinarians and pet owners new treatment options for pets. She says:
“We are more than pleased to have gained such a dedicated and experienced collaboration partner.”
